Directly acting antivirals for hepatitis C and antiretrovirals

Seden, Kay; Back, David

doi:10.1097/coh.0b013e32834b54dc

Cited by 36 publications

(27 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The incorporation of the new protease inhibitors (PIs) to Peg-IFN/RBV will improve the rate of treatment response in this group of patients, as they did with HCV monoinfected patients [35], [36]. However, in the particular case of HIV protease inhibitors, interactions with antiretroviral treatment will have to be added to the drawbacks of the new PIs, along with a higher rate of adverse events and the cost of HIV/HCV co-infected patients [37]. This will be a key aspect of HCV treatment for HIV co-infected patients, since some will need to switch antiretroviral treatment, which has various clinical limitations.…”

Section: Discussionmentioning

confidence: 99%

Natural Killer KIR3DS1 Is Closely Associated with HCV Viral Clearance and Sustained Virological Response in HIV/HCV Patients

et al. 2013

View full text Add to dashboard Cite

AimTo evaluate the influence of the presence of the killer cell immunoglobulin-like receptor (KIR) 3DS1 on HCV treatment response in HIV/HCV genotype 1 co-infected patientsMethodsHIV/HCV co-infected patients were included. KIR3DS1, their specific HLA-B ligands and IL28B gene were genotyped. Reductions of plasma HCV RNA levels between baseline and week 1, week 2 and week 4 were analyzed for IL28B genotype and KIR3DS1 (HLA Bw4 or Bw6). Rapid and sustained virological response (RVR and SVR) rates were also analyzed.ResultsSixty HIV/HCV genotype 1 co-infected patients were included. Patients with KIR3DS1 and Bw4 had higher rates of HCV viral decline than those who were not carriers of KIR3DS1 (week1: p = 0.01; week2: p = 0.038; week 4: p = 0.03). Patients carrying KIR3DS1/Bw4 had higher rates of RVR and SVR than those who did not carry KIR3DS1 (RVR: 46.15% versus 17.02%, p = 0.012; SVR: 63.6% versus 13 26.5%, p = 0.031). With respect to patients carrying the IL28B-CC genotype, those with KIR3DS1/Bw4 had greater rates of HCV viral clearance (week1: p<0.001; week2: p = 0.01; week 4: p = 0.02), RVR (p = 0.015) and SVR (p = 0.029) than those not carrying KIR3DS1.ConclusionOur results show that the KIR3DS1 genotype has a positive effect on HCV viral clearance during the first weeks of Peg-IFN/RBV treatment in HCV/HCV co-infected patients bearing genotype 1, and higher RVR and SVR rates.

show abstract

Section: Discussionmentioning

confidence: 99%

Natural Killer KIR3DS1 Is Closely Associated with HCV Viral Clearance and Sustained Virological Response in HIV/HCV Patients

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Table 4 summarizes the main pharmacokinetic and metabolic parameters of current DAA. This concern must be particularly emphasized in special patient populations, such as HIV--HCV coinfected individuals, in whom potential interactions between DAA and ARV may be frequent and underestimated [71][72][73][74][75][76]. Moreover, as the presence of co-morbidities and the need for further medications is growing as population ages, proper information on drug interactions is becoming a critical aspect of clinical care.…”

Section: Basics Of Drug Interactionsmentioning

confidence: 99%

Dual antiviral therapy for HIV and hepatitis C – drug interactions and side effects

Esposito

Labarga

Barreiro

et al. 2015

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

The safety profile of current DAA and the most recently approved ARV is quite favorable. Interactions between DAA and ARV could be frequent in clinical practice. The most common drug interactions affect drug metabolism by inducing or inhibiting the cytochrome P450 system, leading to abnormal drug exposures. Throughout this mechanism HCV and HIV protease inhibitors interact, especially when co-formulated with ritonavir as a pharmacoenhancer, and non-nucleoside HCV and HIV polymerase inhibitors. In contrast, HIV and HCV nucleos(t)ide polymerase inhibitors, and most HCV NS5A inhibitors (i.e., ledipasvir) and HIV integrase inhibitors (i.e., dolutegravir), do not or only marginally affect CYP450, and therefore are free of significant drug interactions. Exposure to HIV and HCV nucleos(t)ide analogues (i.e., tenofovir and sofosbuvir, respectively) is subject to induction/inhibition of drug transporters (i.e., P-glycoprotein).

show abstract

“…La coadministración con fármacos que dependan en gran medida de estas enzimas para su aclaramiento, como los agentes inmunosupresores inhibidores de la calcineurina (tacrolimus y, en menor medida, ciclosporina) y antirretrovirales podría incrementar de forma tan intensa los niveles plasmáticos de estos últimos que lleguen a producirse episodios adversos importantes e incluso riesgo vital. Ello contraindicaría el empleo de los inhibidores de proteasas en caso de administración conjunta con estos fármacos 78,79 .…”

Section: Otros Grupos Especiales: Trasplante Hepático Y Coinfección Vunclassified

Indicaciones actuales de tratamiento triple para la hepatitis C

Pérez

Castroagudı́n

Muñoz

2012

Gastroenterología y Hepatología

View full text Add to dashboard Cite

Directly acting antivirals for hepatitis C and antiretrovirals

Cited by 36 publications

References 43 publications

Natural Killer KIR3DS1 Is Closely Associated with HCV Viral Clearance and Sustained Virological Response in HIV/HCV Patients

Natural Killer KIR3DS1 Is Closely Associated with HCV Viral Clearance and Sustained Virological Response in HIV/HCV Patients

Dual antiviral therapy for HIV and hepatitis C – drug interactions and side effects

Indicaciones actuales de tratamiento triple para la hepatitis C

Contact Info

Product

Resources

About